On May 8th, according to the financial report recently released by Eli Lilly Pharmaceuticals, it was affected by Mounjaro, Zepbound, and Weixuan& Reg; And Ou Tangjing; Reg; Driven by a year-on-year increase of 26% in revenue in the first quarter of 2024; Core earnings per share (EPS) increased by 66% to reach $2.48; According to non GAAP accounting standards, it increased by 59% to reach $2.58. The company's annual revenue guidance for 2024 has been increased by 2 billion US dollars; The core earnings per share guidance has been increased by $1.25 to $13.05 to $13.55, while under non GAAP accounting standards, the core earnings per share guidance has been increased by $1.30 to $13.50 to $14.00.